HR+ BC patients exhibited high levels of IL-1β leading to metastasis [77], downregulation of ERα [76], chemo-resistance, and endocrine resistance [77], which has been shown to be a great challenge in the treatment of hormonal BC patients [151]. This evidence concerns the gene IL1B and breast cancer.